Ultrasound-guided injection of platelet-rich plasma or cord blood platelet-rich plasma in nonunion: a randomized controlled trial

Plain language summary Although the regenerative capacity of bone tissue is well recognized, the fracture repair process may be impaired by unfavorable conditions resulting in delayed union or complete nonunion. In this scenario, the use of autologous blood derivates to accelerate bone healing has been proposed. The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP) and cord blood PRP (PRPc) in bone nonunion. PRPc contains high levels of cytokines and growth factors, has low immunogenicity and can be successfully stored until use. This study verified that bone consolidation was similar in PRP and PRPc treatments, thus supporting PRPc as a valid therapeutic option when clinical conditions discourage the use of autologous blood derivates.Aim: To compare the ability of autologous platelet-rich plasma (PRP) and cord blood PRP (PRPc) to accelerate bone healing. Patients & methods: 71 patients with mechanically stable nonunion were treated weekly (3 consecutive weeks) with ultrasound-guided percutaneous injections of PRP or PRPc in a controlled randomized clinical trial. The primary outcome was healing (12 months) and secondary outcomes were radiological evolution (2 and 6 months) and changes in pain intensity (6 months). Results & conclusion: Bone consolidation was assessed over time without significant differences between PRP and PRPc treatment. In patients with persistent nonunion, pain perception decreased more after PRP treatment. PRPc appears to be a valid alternative when specific clinical conditions suggest avoiding the use of autologous blood products.